GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

DaShenLin Pharmaceutical Group Co 603233.SS · CNY

Consumer Staples · Shanghai · 🇨🇳 China

Compare

20.54

-4.42%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥27.50bn

FY2016FY2025

Net income

CN¥1.24bn

FY2016FY2025

Free cash flow

CN¥4.87bn

FY2016FY2025

Shareholders' equity

CN¥7.37bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥27.50bnCN¥26.50bnCN¥24.53bnCN¥21.25bnCN¥16.76bnCN¥14.58bnCN¥11.14bnCN¥8.86bnCN¥7.42bnCN¥6.27bn
Gross profitCN¥9.44bnCN¥9.07bnCN¥8.74bnCN¥8.02bnCN¥6.37bnCN¥5.59bnCN¥4.39bnCN¥3.68bnCN¥2.98bnCN¥2.52bn
Research and developmentCN¥41.3mCN¥51.7mCN¥80.9mCN¥74.4mCN¥44.6mCN¥4.7mCN¥434,485CN¥608,998—CN¥168,000
Operating incomeCN¥2.10bnCN¥1.35bnCN¥1.63bnCN¥1.42bnCN¥1.10bnCN¥1.45bnCN¥916.3mCN¥714.2mCN¥650.0mCN¥578.4m
Net incomeCN¥1.24bnCN¥914.8mCN¥1.17bnCN¥1.04bnCN¥791.2mCN¥1.06bnCN¥702.7mCN¥531.6mCN¥475.0mCN¥430.2m
Diluted earnings per share1.090.811.030.910.720.930.950.720.640.64

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥26.49bnCN¥26.44bnCN¥24.12bnCN¥20.84bnCN¥17.34bnCN¥12.33bnCN¥8.67bnCN¥6.54bnCN¥5.82bnCN¥3.58bn
Cash and short-term investments—CN¥6.23bnCN¥4.46bnCN¥4.59bnCN¥2.90bnCN¥4.44bnCN¥1.72bnCN¥1.33bnCN¥1.08bnCN¥668.4m
Total liabilitiesCN¥17.83bnCN¥18.30bnCN¥16.19bnCN¥13.98bnCN¥11.40bnCN¥6.76bnCN¥4.34bnCN¥3.45bnCN¥3.02bnCN¥2.24bn
DebtCN¥463.0mCN¥6.32bnCN¥5.44bnCN¥5.93bnCN¥5.28bnCN¥1.40bnCN¥329.3mCN¥352.8mCN¥515.2mCN¥409.2m
Shareholders' equityCN¥7.37bnCN¥6.90bnCN¥6.82bnCN¥6.21bnCN¥5.48bnCN¥5.38bnCN¥4.24bnCN¥3.04bnCN¥2.75bnCN¥1.32bn
Shares outstanding1,132m1,132m1,138m1,136m1,096m1,137m743m737m738m668m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥5.35bnCN¥3.11bnCN¥3.17bnCN¥3.76bnCN¥1.55bnCN¥1.95bnCN¥1.71bnCN¥873.6mCN¥640.4mCN¥495.6m
Capital spending−CN¥484.8m−CN¥1.48bn−CN¥1.80bn−CN¥1.03bn−CN¥1.29bn−CN¥792.3m−CN¥501.4m−CN¥554.4m−CN¥668.5m−CN¥307.4m
Free cash flowCN¥4.87bnCN¥1.63bnCN¥1.38bnCN¥2.72bnCN¥260.0mCN¥1.16bnCN¥1.21bnCN¥319.2m−CN¥28.1mCN¥188.2m
Dividends paid−CN¥782.1m−CN¥753.2m−CN¥569.5m−CN¥395.5m−CN¥526.9m−CN¥328.2m−CN¥240.0m−CN¥262.7m−CN¥20.5m−CN¥160.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥7.02bnCN¥6.97bnCN¥7.43bnCN¥6.55bnCN¥6.57bnCN¥6.96bnCN¥6.77bnCN¥6.39bn
Gross profitCN¥2.47bnCN¥2.51bnCN¥2.45bnCN¥2.27bnCN¥2.29bnCN¥2.43bnCN¥2.23bnCN¥2.20bn
Operating incomeCN¥656.1mCN¥734.3mCN¥445.7mCN¥441.6mCN¥475.6mCN¥650.1mCN¥167.5mCN¥281.3m
Net incomeCN¥415.6mCN¥511.1mCN¥154.2mCN¥282.8mCN¥338.2mCN¥460.0mCN¥56.6mCN¥200.5m
Diluted earnings per share0.370.450.140.250.300.410.050.18
Cash from operations———CN¥818.0mCN¥1.14bnCN¥1.77bnCN¥596.0mCN¥742.0m
Capital spending−CN¥199.0m−CN¥115.0m−CN¥126.0m−CN¥161.0m−CN¥109.0m−CN¥87.0m−CN¥45.0m−CN¥173.0m
Free cash flow———CN¥657.0mCN¥1.03bnCN¥1.68bnCN¥551.0mCN¥569.0m
Total assetsCN¥25.85bnCN¥26.83bnCN¥26.49bnCN¥26.08bnCN¥25.45bnCN¥26.78bnCN¥26.44bnCN¥25.88bn
Cash and short-term investments———CN¥6.61bnCN¥5.94bnCN¥6.74bnCN¥6.23bnCN¥5.72bn
DebtCN¥436.7mCN¥500.9mCN¥463.0mCN¥7.38bnCN¥2.41bnCN¥3.12bnCN¥3.62bnCN¥9.10bn
Shareholders' equityCN¥7.73bnCN¥7.87bnCN¥7.37bnCN¥7.23bnCN¥7.33bnCN¥7.36bnCN¥6.90bnCN¥6.87bn

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin34.3%34.2%35.6%37.8%38.0%38.3%
Operating margin7.6%5.1%6.7%6.7%6.6%9.9%
Net margin4.5%3.5%4.8%4.9%4.7%7.3%
Return on equity16.8%13.3%17.1%16.7%14.4%19.7%
Return on assets4.7%3.5%4.8%5.0%4.6%8.6%
Free cash flow yield29.4%23.1%24.9%24.0%14.8%13.8%
Revenue growth3.8%8.0%15.5%26.8%14.9%30.9%
Earnings growth35.0%-21.6%12.6%30.9%-25.5%51.2%
Current ratio0.89x0.92x0.94x1.10x1.10x1.52x
Debt to equity0.06x0.53x0.35x0.35x0.26x0.26x
Equity ratio27.8%26.1%28.3%29.8%31.6%43.7%
Interest coverage27.09x4.80x5.93x5.25x4.62x37.63x
R&D as a share of sales0.2%0.2%0.3%0.4%0.3%0.0%
Buybacks as a share of market value0.0%0.5%-0.1%-3.7%3.6%-53.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue9.0%13.5%18.0%
Operating income13.8%7.7%14.4%
Net income6.0%3.1%12.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin34.3%35.3%36.0%37.0%
Operating margin6.4%6.5%6.9%7.3%
Net margin4.0%4.4%4.7%5.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings16.218.624.336.240.548.526.620.529.8
Price to sales0.70.61.11.81.93.51.71.21.9

Dividends and splits

Per share, in the currency the company pays

Paid for 8 years. Last went ex-dividend on 26 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.490.650.620.600.4170.4630.3470.223
  • 6-for-5 split · 9 Jun 2023
  • 6-for-5 split · 13 Jun 2022
  • 6-for-5 split · 10 Jun 2021
  • 6-for-5 split · 17 Jun 2020
  • 13-for-10 split · 30 May 2019

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.